Massachusetts General Hospital

Infraredx, Massachusetts General Hospital collaborate on cardiovascular imaging devices

Wednesday, December 17, 2014 12:26 PM

Infraredx, a Burlington, Mass.-based cardiovascular imaging company, is collaborating with Massachusetts General Hospital (MGH) and coronary imaging researcher Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.

More... »


ALS Association awards research funds for C9orf72 clinical trials

Friday, December 12, 2014 03:34 PM

The ALS Association, a national nonprofit organization based in Wash. D.C., has awarded $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

More... »


NIH launches Illuminating the Druggable Genome to find potential drug targets

Wednesday, October 29, 2014 01:09 PM

NIH has announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. The effort is part of an NIH Common Fund three-year pilot project called Illuminating the Druggable Genome (IDG). For the initial phase of the program, NIH has allocated $5.8 million to eight institutions and for intramural resources.

More... »

Center for Connected Health, Daiichi Sankyo ink mobile app agreement

Thursday, October 23, 2014 01:19 PM

The Center for Connected Health, a division of Partners HealthCare, a Boston-based healthcare delivery system founded by Harvard Medical School affiliated teaching institutions Brigham and Women's Hospital and Massachusetts General Hospital, has announced a co-development agreement with Japanese pharmaceutical Daiichi Sankyo to create a mobile app to serve as a coaching platform for patients with atrial fibrillation who have been prescribed oral anticoagulation therapy.

More... »

PPD acquires RCT Logic's exclusive license to clinical trial design technology

Monday, September 8, 2014 01:50 PM

Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based CRO, has acquired RCT Logic's exclusive license from Massachusetts General Hospital (MGH) for the portfolio of patents related to its sequential parallel comparison design (SPCD).

More... »

AWARE for All Clinical Research Education Day returns to Boston

Monday, August 4, 2014 02:53 PM

The Center for Information and Study on Clinical Research Participation (CISCRP), a nonprofit organization dedicated to engaging the public and patients as partners in the clinical research process, has announced the return of AWARE for All Boston, a free event designed to promote understanding and dialogue around clinical research participation.

More... »

NIH adds six clinical sites in Undiagnosed Diseases Network

Wednesday, July 2, 2014 12:40 PM

The NIH has awarded grants to six medical centers around the country to select from the most difficult-to-solve medical cases and together develop effective approaches to diagnose them. The new clinical sites added to the NIH Undiagnosed Diseases Network (UDN) will conduct clinical evaluation and scientific investigation in cases that involve patients with prolonged, undiagnosed conditions.

More... »

AZTherapies to start enrolling for phase III study of ALZT-OP1 in early Alzheimer's

Friday, May 23, 2014 11:27 AM

AZTherapies, a company developing novel treatments for Alzheimer's disease based on technology licensed from Massachusetts General Hospital, has received notice from FDA that it may proceed with the phase III clinical study submitted in its IND application. This study is for its lead program, ALZT-OP1, a novel combination therapy for the prevention and treatment of early Alzheimer's disease (AD).

More... »

Infinity appoints Baselga, Berkowitz to board of directors

Thursday, March 13, 2014 11:26 AM

Infinity Pharmaceuticals has appointed José Baselga M.D., Ph.D., and Jeff Berkowitz as independent members of its board of directors. Baselga, physician-in-chief at Memorial Sloan-Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Berkowitz, as the president of Walgreens Boots Alliance Development in Europe, has experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement.

More... »

MGH, Broad Institute, Amgen collaborate on IBD therapies

Friday, January 17, 2014 11:44 AM

Massachusetts General Hospital (MGH), the Broad Institute and Amgen have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists with experience in clinical medicine, IBD biology, human genetics, genomic technology and drug discovery to work together to help create a new world of therapeutic options for IBD patients.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs